RxDoctor Payments Data

Vicki Lederle, NP

Family · Logansport, INNPI 1508454778

Payments from drug & device makers

$443in general payments, 2019–2025

Across 13 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$144
  • Exact Sciences$115
  • Eisai Inc.$97
  • Procept Biorobotics Corporation$28
  • Bayer$20
  • AbbVie$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$443 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$65,936
Medicare patients
300
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$39,519
MounjaroTirzepatide33$39,203
EliquisApixaban26$32,766
JardianceEmpagliflozin22$20,482
Nurtec OdtRimegepant Sulfate11$18,904
QuliptaAtogepant13$16,380
Emgality PenGalcanezumab-Gnlm20$15,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,010
EntrestoSacubitril/Valsartan13$13,095
FarxigaDapagliflozin Propanediol12$7,278
SymbicortBudesonide/Formoterol Fumarate15$6,545
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,007
Duloxetine Hcl86$2,812
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$2,754
Divalproex Sodium ErDivalproex Sodium30$2,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$39,51941 claims
AbbVieQulipta$14$16,38013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Logansport

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →